Cancer risk among 20 120 Swedish patients with Crohn’s disease, identified in two regional and population based cohorts and/or in the nationwide and population based register of inpatient care
| Cancer type | Crohn’s disease (n = 20 120*) | |||||
|---|---|---|---|---|---|---|
| Regional cohorts (n = 3561) | Inpatient register (n = 19 024) | |||||
| O | E | SIR (95% CI) | O | E | SIR (95% CI) | |
| *The sum of 3651 and 19 024 exceeded 20 120 because of overlap between the cohorts. | ||||||
| CLL, chronic lymphocytic leukaemia. Cancers coded according to ICD-7. | ||||||
| Follow up from 1969 until 2001. Observed (O) and expected (E) number of cases, and standardised incidence ratio (SIR) with 95% confidence interval (95% CI). First year of follow up excluded. | ||||||
| All solid or haematopoietic sites (140–209) | 318 | 309.1 | 1.03 (0.9–1.2) | 1188 | 1069.3 | 1.11 (1.0–1.2) |
| All haematopoietic cancers (200–209) | 27 | 23.4 | 1.15 (0.8–1.7) | 98 | 80.1 | 1.21 (1.0–1.5) |
| Malignant lymphomas including CLL (200–202, 204.1) | 18 | 14.1 | 1.28 (0.8–2.0) | 65 | 49.1 | 1.32 (1.0–1.7) |
| Non-Hodgkin lymphomas (200, 202) | 14 | 9.68 | 1.45 (0.8–2.4) | 53 | 34.2 | 1.55 (1.2–2.0) |
| Hodgkin’s lymphoma (201) | 2 | 1.8 | 1.11 (0.1–4.0) | 6 | 5.8 | 1.03 (0.4–2.2) |
| CLL (204.1) | 2 | 2.6 | 0.78 (0.09–2.8) | 6 | 9.0 | 0.66 (0.2–1.4) |
| Multiple myeloma (203) | 3 | 3.8 | 0.79 (0.2–2.3) | 10 | 13.1 | 0.76 (0.4–1.4) |
| All leukaemias excluding CLL (204–207, 209) | 5 | 4.6 | 1.09 (0.4–2.5) | 21 | 15.7 | 1.34 (0.8–2.0) |
| Acute lymphatic leukaemia (204.0, 204.9) | 1 | 0.5 | 2.09 (0.05–11.6) | 1 | 1.7 | 0.60 (0.02–3.4) |
| Acute myeloid leukaemia (205.0, 205.9) | 2 | 2.2 | 0.89 (0.1–3.2) | 4 | 7.8 | 0.51 (0.1–1.3) |
| Chronic myeloid leukaemia (205.1) | 1 | 0.9 | 1.10 (0.03–6.1) | 8 | 2.9 | 2.80 (1.2–5.5) |
| Other leukaemias (206.0–1, 207.0–3, 207.9, 209) | 1 | 1.0 | 1.04 (0.03–5.8) | 8 | 3.4 | 2.38 (1.0–4.7) |
| Polycytaemia vera (209) | 1 | 1.0 | 1.04 (0.03–5.8) | 2 | 3.1 | 0.65 (0.1–2.3) |